This company listing is no longer active
Synairgen Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Joseph Colliver
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 1.7yrs |
| CEO ownership | n/a |
| Management average tenure | 3.8yrs |
| Board average tenure | less than a year |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -UK£7m |
| Mar 31 2024 | n/a | n/a | -UK£8m |
| Dec 31 2023 | UK£197k | UK£30k | -UK£8m |
Compensation vs Market: Insufficient data to establish whether Joseph's total compensation is reasonable compared to companies of similar size in the German market.
Compensation vs Earnings: Insufficient data to compare Joseph's compensation with company performance.
CEO
Joseph Colliver (45 yo)
Mr. Joseph Tregonning Colliver, F.C.A., serves as Chief Financial Officer & Executive Director of Synairgen plc since November 06, 2023 and also serves as its Chief Executive Officer since July 01, 2025. H...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, CFO & Executive Director | 1.7yrs | UK£197.41k | no data | |
| Co-Founder & Member of Scientific Advisory Board | no data | UK£40.00k | 0% € 0 | |
| Executive Chairman | less than a year | no data | no data | |
| Co-Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Co-Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Chief Regulatory Officer | 3.8yrs | no data | no data | |
| Senior VP & Head of Clinical Operations | 13.6yrs | no data | no data | |
| Senior VP and Head of CMC & Quality | 3.8yrs | no data | no data | |
| Head of Laboratory | 6.3yrs | no data | no data | |
| Chief Medical Officer | 1.8yrs | no data | no data | |
| Company Secretary | 4.5yrs | no data | no data |
Experienced Management: OMY's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, CFO & Executive Director | 1.7yrs | UK£197.41k | no data | |
| Co-Founder & Member of Scientific Advisory Board | no data | UK£40.00k | 0% € 0 | |
| Executive Chairman | less than a year | no data | no data | |
| Co-Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Co-Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Executive Director | less than a year | no data | no data | |
| Independent Non-Executive Director | less than a year | no data | no data | |
| Member of Scientific Advisory Board | 19.3yrs | UK£40.00k | 0% € 0 | |
| Member of Scientific Advisory Board | no data | UK£45.00k | no data |
Experienced Board: OMY's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/05 02:29 |
| End of Day Share Price | 2025/04/08 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Synairgen plc is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Cavendish |
| Mark Brewer | Cavendish |